Processing...
Clinical Trials for Melanoma
Search
Search
There are 157 active trials for advanced/metastatic melanoma.
Click on a trial to see more information.
157 trials meet filter criteria.
Sort by:
TrialFetch AI summary: Adults with advanced solid tumors refractory to standard therapy (ECOG 0–1, measurable disease) receive a single intravenous infusion of IDOV-Immune (VM-002), a genetically engineered oncolytic vaccinia virus designed for tumor-selective replication and lysis with immune-stimulating transgenes to enhance antitumor immunity. Key exclusions include prior oncolytic virus therapy, recent vaccinia/smallpox vaccination, active autoimmune disease requiring systemic therapy, significant cardiopulmonary disease, uncontrolled infection, and unstable/untreated CNS metastases.
ClinicalTrials.gov ID: NCT06910657
TrialFetch AI summary: Enrolls adults with relapsed/refractory or treatment-ineligible advanced/metastatic solid tumors (ECOG 0–1) who have at least two injectable lesions, with emphasis on cutaneous and head/neck cancers (e.g., cSCC, BCC, melanoma, Merkel cell carcinoma, HNSCC) including anti–PD-1–refractory cohorts. Patients receive intratumoral MQ710/MQ719, a non-replicating modified vaccinia Ankara virotherapy (E5R-deleted to enhance cGAS/STING signaling and engineered to express Flt3L and OX40L), given in escalating multi-dose schedules alone or combined with systemic pembrolizumab (PD-1 inhibitor).
ClinicalTrials.gov ID: NCT05859074
TrialFetch AI summary: Adults (≥18) with locally advanced or metastatic solid tumors that are refractory/intolerant to standard therapies or lack standard options (ECOG 0–2; no active CNS/leptomeningeal metastases) receive IV JMT108 every 2 weeks (with possible alternate schedules in expansion). JMT108 is a fully human anti–PD-1 antibody fused to IL-15 intended to combine checkpoint blockade with IL-15–driven activation/proliferation of CD8+ T cells and NK cells, with tumor-specific expansion cohorts including lung, colorectal, hepatocellular, gastric cancers, melanoma, and other solid tumors.
ClinicalTrials.gov ID: NCT07317505
TrialFetch AI summary: Adults with measurable metastatic uveal melanoma (ECOG 0–2), including heavily pretreated patients (HLA-A*02:01–positive patients generally expected to have received prior tebentafusp when available), are treated with NBM-BMX, an oral HDAC8-selective histone deacetylase inhibitor aimed at epigenetic modulation to promote tumor cell-cycle arrest and apoptosis. NBM-BMX is given as empty-stomach oral capsules twice daily in continuous 28-day cycles with dose escalation (100–400 mg BID) followed by expansion until progression or unacceptable toxicity.
ClinicalTrials.gov ID: NCT07136181
TrialFetch AI summary: Adults with unresectable or metastatic melanoma that has progressed after at least one prior systemic therapy including anti–PD-1 (ECOG 0–1; treated/stable brain metastases allowed) receive DOC1021 (dubodencel), a personalized autologous dendritic-cell vaccine made from mobilized peripheral blood cells and loaded with patient-specific tumor antigens (tumor lysate + amplified tumor mRNA) to induce Th1/cytotoxic T-cell responses, with peginterferon alfa-2a as an immune adjuvant. Treatment includes filgrastim mobilization with leukapheresis, two image-guided perinodal DOC1021 injections 2 weeks apart with 4 weeks of weekly peginterferon (optional 6‑month booster with additional peginterferon), and anti–PD-1 is held until ~6 weeks after the first DOC1021 dose (may be resumed later per protocol).
ClinicalTrials.gov ID: NCT07288112
TrialFetch AI summary: This trial involves adult patients with advanced or metastatic solid tumors such as melanoma and non-small cell lung cancer who have relapsed after standard treatments, testing the investigational agent ST-067 alone or with pembrolizumab and obinutuzumab to enhance immune response against tumor cells.
ClinicalTrials.gov ID: NCT04787042
TrialFetch AI summary: This trial enrolls adults with unresectable or metastatic melanoma or advanced non-small-cell lung cancer who have progressed after at least anti-PD-1/PD-L1 therapy, using an autologous tumor-infiltrating lymphocyte product (IOV-4001) genetically edited to knock out PD-1 via TALEN technology, administered after lymphodepleting chemotherapy and followed by high-dose IL-2. PD-1 knockout aims to enhance TIL antitumor activity by reducing exhaustion.
ClinicalTrials.gov ID: NCT05361174
TrialFetch AI summary: This trial enrolls adults with advanced or metastatic solid tumors or diffuse large B-cell lymphoma who have exhausted standard therapies, evaluating the investigational oral CBL-B inhibitor NX-1607 (which enhances antitumor immunity by blocking a negative regulator of immune cell activation) as monotherapy or in combination with paclitaxel. Eligible tumor types include ovarian, gastric, head and neck, melanoma, NSCLC, prostate, mesothelioma, triple-negative breast, urothelial, cervical, microsatellite-stable colorectal cancer, and DLBCL/Richter transformation.
ClinicalTrials.gov ID: NCT05107674
TrialFetch AI summary: This study enrolls adults with unresectable, locally advanced, or metastatic antigen-rich solid tumors—including TMB-H, MSI-H/dMMR, virally associated, metastatic colorectal, triple negative breast, platinum-resistant ovarian, metastatic castration-resistant prostate, and NSCLC—who lack standard treatment options. Patients receive STAR0602 (invikafusp alfa), a bifunctional bispecific antibody that selectively activates and expands Vβ6/Vβ10 T cell subsets to enhance antitumor immunity.
ClinicalTrials.gov ID: NCT05592626
TrialFetch AI summary: This trial enrolls adults with recurrent or metastatic GRPR-expressing solid tumors (including mCRPC, HR+/HER2- breast, colorectal, cervical, melanoma, and NSCLC) who have progressed on at least two prior systemic therapies, and treats them with 212Pb-DOTAM-GRPR1, a radiolabeled peptide that targets the gastrin-releasing peptide receptor (GRPR) to deliver alpha particle radiation directly to tumor cells.
ClinicalTrials.gov ID: NCT05283330